Deciphera Pharmaceuticals Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Deciphera Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DCPH, but not buy additional shares or sell existing shares.
View analyst ratings for Deciphera Pharmaceuticals or view top-rated stocks.

9 equities research analysts have issued 1-year price targets for Deciphera Pharmaceuticals' stock. Their DCPH stock forecasts range from $6.00 to $70.00. On average, they expect Deciphera Pharmaceuticals' stock price to reach $26.57 in the next twelve months. This suggests a possible upside of 93.1% from the stock's current price.
View analysts' price targets for Deciphera Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Deciphera Pharmaceuticals' stock was trading at $9.77 at the beginning of 2022. Since then, DCPH shares have increased by 40.8% and is now trading at $13.76.
View the best growth stocks for 2022 here.

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) posted its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.03. The company earned $29.22 million during the quarter, compared to analyst estimates of $27.17 million. Deciphera Pharmaceuticals had a negative net margin of 279.96% and a negative trailing twelve-month return on equity of 79.96%. The firm's quarterly revenue was up 16.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.06) earnings per share.
View Deciphera Pharmaceuticals' earnings history.

3 employees have rated Deciphera Pharmaceuticals CEO Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among Deciphera Pharmaceuticals' employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Deciphera Pharmaceuticals include Karuna Therapeutics (KRTX), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Zai Lab (ZLAB), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), Amicus Therapeutics (FOLD), AbCellera Biologics (ABCL), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT), Indivior (INVVY), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), CureVac (CVAC) and Insmed (INSM).
View all of DCPH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Deciphera Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (8.67%), BlackRock Inc. (7.32%), Vanguard Group Inc. (5.43%), Federated Hermes Inc. (2.96%), Assenagon Asset Management S.A. (1.46%) and Goldman Sachs Group Inc. (1.21%). Company insiders that own Deciphera Pharmaceuticals stock include Brightstar Associates Llc, Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly.
View institutional ownership trends for Deciphera Pharmaceuticals.

DCPH stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Bank of America Corp DE, State Street Corp, Citigroup Inc., Acadian Asset Management LLC, Wellington Management Group LLP, UBS Group AG, and Charles Schwab Investment Management Inc.. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last two years include Daniel Lee Flynn, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, and Thomas Patrick Kelly.
View insider buying and selling activity for Deciphera Pharmaceuticals or view top insider-selling stocks.

DCPH stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., BlackRock Inc., Assenagon Asset Management S.A., PDT Partners LLC, Pinz Capital Management LP, Vanguard Group Inc., Connor Clark & Lunn Investment Management Ltd., and Panagora Asset Management Inc..
View insider buying and selling activity for Deciphera Pharmaceuticals or or view top insider-buying stocks.

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DCPH stock can currently be purchased for approximately $13.76.

Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $911.19 million and generates $96.15 million in revenue each year. The company earns $-299.96 million in net income (profit) each year or ($4.89) on an earnings per share basis.

Deciphera Pharmaceuticals employs 280 workers across the globe.

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for Deciphera Pharmaceuticals is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at [email protected].